AR042651A1 - Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas - Google Patents
Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininasInfo
- Publication number
- AR042651A1 AR042651A1 ARP030104776A ARP030104776A AR042651A1 AR 042651 A1 AR042651 A1 AR 042651A1 AR P030104776 A ARP030104776 A AR P030104776A AR P030104776 A ARP030104776 A AR P030104776A AR 042651 A1 AR042651 A1 AR 042651A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- disorders
- amino
- group
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La presente se refiere a derivados de 1-piperidin-4-il-pirrolidin-3-il-piperazina que tienen una actividad antagonista de neuroquinina, en particular actividad antagonista de NK1, una actividad antagonista de NK1/NK3 combinada y una actividad antagonista de NK1/NK2/NK3 combinada, su preparación, las composiciones que los comprenden y su uso en forma de medicamento, en particular para el tratamiento de la esquizofrenia, ansiedad, depresión, emesis y SII. En vista de su capacidad para antagonizar las acciones de las taquininas bloqueando los receptores de neuroquinina, y en particular antagonizando las acciones de la sustancia P y la Neuroquinina B bloqueando los receptores de NK1, NK2 y NK3, los compuestos de acuerdo con la presente son útiles como medicamento, en particular en el tratamiento profiláctico y terapéutico de las enfermedades mediadas por taquininas, tales como, por ejemplo trastornos del SNC, en particular trastornos esquizoafectivos, depresión, trastornos de ansiedad, trastornos relacionados con el estrés, trastornos del sueno, trastornos cognitivos, trastornos de personalidad, trastornos de alimentación, enfermedades neurodegenerativas, trastornos de adicción, trastornos del humor, disfunción sexual, dolor y otras enfermedades relacionadas con el SNC; inflamación, trastornos alérgicos, emesis, trastornos gastrointestinales, en particular síndrome el intestino irritable (SII); trastornos de piel, enfermedades vasoespásticas, enfermedades fibrosantes y colagenosis; enfermedades relacionadas con la intensificación o supresión inmune y enfermedades reumáticas y control del peso corporal. Reivindicación 1: Un compuesto de acuerdo con la fórmula general (1) las sales de adición con ácidos o bases farmacéuticamente aceptables de los mismos, sus formas estereoquímicamente isoméricas, su forma N-óxido y sus pro-fármacos en donde: n es un número entero, igual a 0, 1, o 2; m es un número entero, igual a 1 o 2, siempre que si m es 2, entonces n es 1; p es un número entero igual a 1 o 2; q es un número entero igual a 0 o 1; Q es O o NR3; X es un enlace covalente o un radical bivalente de fórmula -O-, -S- o -NR3-; cada R3 independientemente uno de otro, es H o alquilo; Cada R1 independientemente uno de otro, se selecciona el grupo de Ar1, Ar1-alquilo y di(Ar1)-alquilo; R2 es Ar2, Ar2-alquilo, di(Ar2)-alquilo, Het1 o Het1-alquilo; Y es un enlace covalente o u radical bivalente de fórmula -C(=O)-SO2 >C=CH-R o >C=N-R, en donde R es H, CN o nitro; cada Alq representa independientemente uno de otro, un enlace covalente, un radical hidrocarbonado bivalente recto o ramificado, saturado o no saturado que tiene de 1 a 6 átomos de carbono; o un radical hidrocarbonado cíclico saturado o no saturado que tiene de 3 a 6 átomos de C; cada radical sustituido opcionalmente sobre uno o más átomos de C con uno o más radicales fenilo, halo, ciano, hidroxi, formilo y amino; L se selecciona del grupo de H, alquilo, alquiloxi, alquiloxialquiloxi, alquilcarboniloxi, alquiloxicarbonilo, mono- y di(alquil)amino, mono y di(alquiloxicarbonil)amino, mono- y di(alquilcarbonil)amino, mono- y di(Ar3)amino, mono- y di(Ar3alquil)amino, mono- y di(Het2)amino, mono- y di(Het2alquil)amino, alquilsulfanilo, admantilo, Ar3, Ar3-oxi, Ar3carbonilo, Het2, Het-oxi y Het2carbonilo; Ar1 es fenilo, opcionalmente sustituido con 1, 2, o 3 sustituyentes, cada uno de ellos independientemente uno de otro, seleccionado del grupo de halo, alquilo, ciano, aminocarbonilo i alquiloxi; Ar2 es naftileno o fenilo, cada uno de ellos opcionalmente sustituido con 1, 2, o 3 sustituyentes, independientemente uno de otro, seleccionado del grupo de halo, nitro, amino, mono- y di(alquil)amino, ciano, alquilo, hidroxi, alquiloxi, carboxilo, alquiloxicarbonilo aminocarbonilo y mono- y di(alquil)aminocarbonilo; Ar3 es naftileno o fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes cada uno de ellos independientemente uno de otro, seleccionado del grupo de alquiloxi, Ar1carboniloxialquio, Ar1alquiloxicarbonilo, Ar1alquiloxialquilo, alquilo, halo, hidroxi, piridinilo, morfolinilo, pirrolidinilo, imidazo[1,2-a]piridinilo, morfonilcarbonilo, pirrolidinilcarbonilo, amino y ciano; Het1 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolilo, pirazolilo, imidazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, y piridazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de quinolinilo, quinoxalinilo, indolilo, bencimidazolilo,benzoxazolilo, bencisoxazolilo, benzotiazolilo, bencisotiazolilo, benzofuranilo, benzotienilo, indanilo y cromenilo; cada radical heterocíclico puede estar opcionalmente sustituido sobre cualquier átomo con uno o más radicales seleccionados del grupo de halo, oxo y alquilo; Het2 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolidinilo, piperazinilo, imidazolidinilo, tetrahidrofuranilo, 2H-pirrolilo, pirrolinilo, imidazolidinilo, pirazolinilo, pirrolilo, imidazolilo, pirazolilo, triazolilo, furanilo, tienilo, oxazolilo, dioxazolilo, oxazolidinilo, isoxazolilo, tiazolilo, tiadiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo y triazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de 2,3-dihidro-benzo[1,4]dioxina, octahidro-benzo[1,4]dioxina, benzopiperidinilo, quinolinilo, quinoxalinilo, indolilo, isoindolilo, cromanilo, benzoimidazolilo, imidazo[1,2-a]piridinilo, benzoxazolilo, benzoisoxazolilo, benzotiazolilo, benzoisotiazolilo, benzofuranilo y benzotienilo; o un radical tricíclico heterocíclico 8,9-dihidro-4H-1-oxa-3,5,7a-triaza-ciclopenta[f]azulenilo; cada radical puede estar opcionalmente sustituido con uno o más radicales seleccionados del grupo de Ar1, Ar1alquilo, Ar1alquiloxialquilo, halo, hidroxi, alquilo, piperidinilo, pirrolilo, tienilo, oxo, alquiloxi, alquilcarbonilo, Ar1carbonilo, mono- y di(alquil)aminoalquilo, alquiloxialquilo y alquiloxicarbonilo; y alquilo es un radical hidrocarbonado saturado recto o ramificado que tiene de 1 a 6 átomos de C o un radical hidrocarbonado cíclico saturado que tiene de 3 a 6 átomos de C; opcionalmente sustituido sobre uno o más átomos de C con uno o más radicales del grupo de fenilo, halo, ciano, oxo, hidroxi, formilo y amino.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0214831 | 2002-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042651A1 true AR042651A1 (es) | 2005-06-29 |
Family
ID=32668698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104776A AR042651A1 (es) | 2002-12-23 | 2003-12-22 | Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7795261B2 (es) |
| EP (1) | EP1581518B1 (es) |
| JP (1) | JP4746878B2 (es) |
| KR (1) | KR101049073B1 (es) |
| CN (1) | CN100586945C (es) |
| AR (1) | AR042651A1 (es) |
| AT (1) | ATE500242T1 (es) |
| AU (1) | AU2003302488B2 (es) |
| BR (1) | BR0317658A (es) |
| CA (1) | CA2508657C (es) |
| CL (1) | CL2003002725A1 (es) |
| CY (1) | CY1112601T1 (es) |
| DE (1) | DE60336266D1 (es) |
| DK (1) | DK1581518T3 (es) |
| EA (1) | EA009078B1 (es) |
| ES (1) | ES2361161T3 (es) |
| HK (1) | HK1087703A1 (es) |
| HR (1) | HRP20050556B1 (es) |
| IL (1) | IL169336A (es) |
| JO (1) | JO2696B1 (es) |
| MX (1) | MXPA05006887A (es) |
| MY (1) | MY145135A (es) |
| NO (1) | NO331174B1 (es) |
| NZ (1) | NZ541035A (es) |
| PA (1) | PA8593301A1 (es) |
| PL (1) | PL376048A1 (es) |
| PT (1) | PT1581518E (es) |
| SI (1) | SI1581518T1 (es) |
| TW (1) | TWI329109B (es) |
| UA (1) | UA80584C2 (es) |
| WO (1) | WO2004056799A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2847160A1 (fr) * | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| EA015517B1 (ru) | 2004-04-13 | 2011-08-30 | Инсайт Корпорейшн | Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора |
| WO2005123081A2 (en) * | 2004-06-22 | 2005-12-29 | Janssen Pharmaceutica N.V. | (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US7635698B2 (en) * | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| CA2599186C (en) * | 2005-03-08 | 2014-12-09 | Janssen Pharmaceutica N.V. | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists |
| DE102005038947A1 (de) * | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| WO2008060621A2 (en) * | 2006-11-17 | 2008-05-22 | Abbott Laboratories | Aminopyrrolidines as chemokine receptor antagonists |
| RU2442786C2 (ru) * | 2007-03-31 | 2012-02-20 | Интервет Интернэшнл Б.В. | Способы получения зилпатерола и его солей |
| US8362006B2 (en) | 2007-03-31 | 2013-01-29 | Intervet International B.V. | Processes for making zilpaterol and salts thereof |
| EP2142553B1 (en) * | 2007-03-31 | 2015-08-19 | Intervet International B.V. | Processes for making zilpaterol and salts thereof |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX2009013115A (es) | 2007-06-07 | 2010-01-15 | Hoffmann La Roche | Derivados de prolinamida como antagonistas de nk3. |
| JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| US8507535B2 (en) * | 2010-07-07 | 2013-08-13 | Hoffmann-La Roche Inc. | Methyl-pyrrolidine ether derivatives |
| NZ704666A (en) * | 2012-08-23 | 2018-05-25 | Alios Biopharma Inc | Compounds for the treatment of paramoxyvirus viral infections |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| PL3297631T3 (pl) | 2015-05-18 | 2020-03-31 | Nerre Therapeutics Limited | Antagoniści receptora NK-1/NK-3 do leczenia uderzeń gorąca |
| JOP20200227A1 (ar) | 2018-03-14 | 2020-09-13 | Kandy Therapeutics Ltd | تركيبة صيدلانية جديدة تشتمل على مضادات مستقبلة ثنائية من نيوروكينين-1/نيوروكينين-3 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW382017B (en) | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| WO2001030348A1 (en) | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| US6642226B2 (en) * | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| FR2820426B1 (fr) * | 2001-02-07 | 2007-05-11 | Condat Sa | Gel d'isolation thermique a reticulation controlee pour les lignes de transport d'hydrocarbures petroliers |
| MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
-
2003
- 2003-12-15 JO JO2003174A patent/JO2696B1/en active
- 2003-12-17 SI SI200331992T patent/SI1581518T1/sl unknown
- 2003-12-17 DE DE60336266T patent/DE60336266D1/de not_active Expired - Lifetime
- 2003-12-17 CN CN200380106356A patent/CN100586945C/zh not_active Expired - Fee Related
- 2003-12-17 ES ES03810849T patent/ES2361161T3/es not_active Expired - Lifetime
- 2003-12-17 US US10/540,447 patent/US7795261B2/en not_active Expired - Fee Related
- 2003-12-17 NZ NZ541035A patent/NZ541035A/en not_active IP Right Cessation
- 2003-12-17 AT AT03810849T patent/ATE500242T1/de active
- 2003-12-17 UA UAA200505412A patent/UA80584C2/uk unknown
- 2003-12-17 CA CA2508657A patent/CA2508657C/en not_active Expired - Fee Related
- 2003-12-17 KR KR1020057009197A patent/KR101049073B1/ko not_active IP Right Cessation
- 2003-12-17 WO PCT/EP2003/051041 patent/WO2004056799A2/en active Application Filing
- 2003-12-17 DK DK03810849.4T patent/DK1581518T3/da active
- 2003-12-17 JP JP2004561504A patent/JP4746878B2/ja not_active Expired - Fee Related
- 2003-12-17 BR BR0317658-4A patent/BR0317658A/pt not_active IP Right Cessation
- 2003-12-17 EA EA200501041A patent/EA009078B1/ru not_active IP Right Cessation
- 2003-12-17 PL PL03376048A patent/PL376048A1/xx not_active Application Discontinuation
- 2003-12-17 MX MXPA05006887A patent/MXPA05006887A/es active IP Right Grant
- 2003-12-17 AU AU2003302488A patent/AU2003302488B2/en not_active Ceased
- 2003-12-17 PT PT03810849T patent/PT1581518E/pt unknown
- 2003-12-17 EP EP03810849A patent/EP1581518B1/en not_active Expired - Lifetime
- 2003-12-19 MY MYPI20034909A patent/MY145135A/en unknown
- 2003-12-19 PA PA20038593301A patent/PA8593301A1/es unknown
- 2003-12-22 AR ARP030104776A patent/AR042651A1/es unknown
- 2003-12-22 TW TW092136343A patent/TWI329109B/zh not_active IP Right Cessation
- 2003-12-22 CL CL200302725A patent/CL2003002725A1/es unknown
-
2005
- 2005-06-15 HR HRP20050556AA patent/HRP20050556B1/hr not_active IP Right Cessation
- 2005-06-22 IL IL169336A patent/IL169336A/en not_active IP Right Cessation
- 2005-07-21 NO NO20053569A patent/NO331174B1/no not_active IP Right Cessation
-
2006
- 2006-07-14 HK HK06107904.4A patent/HK1087703A1/xx not_active IP Right Cessation
-
2011
- 2011-06-01 CY CY20111100532T patent/CY1112601T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042651A1 (es) | Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas | |
| AU2019263294B2 (en) | Substituted heterocyclic inhibitors of PTPN11 | |
| CA2499903A1 (en) | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
| CA2509406A1 (en) | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| CA2561975A1 (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| AR035667A1 (es) | Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
| CA2561944A1 (en) | Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists | |
| AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
| CN102131807A (zh) | 吡唑并吡啶激酶抑制剂 | |
| BR112019011801A2 (pt) | composto, composição farmacêutica e método de inibição de dlk, método de tratamento de uma doença mediada por dlk, método de tratamento de câncer e redução do desenvolvimento de um distúrbio neurológico induzido por quimioterapia e método para alcançar um efeito em um paciente | |
| KR20100023040A (ko) | 폴리사이클릭 구아닌 유도체 및 이의 용도 | |
| AR052342A1 (es) | Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores | |
| AR054231A1 (es) | Composiciones farmaceuticas | |
| WO2018044808A1 (en) | Inhibitors of dual leucine ziper (dlk) kinase for the treatment of disease | |
| CN101501009A (zh) | Cgrp受体拮抗剂 | |
| AR045913A1 (es) | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina | |
| CA3194376A1 (en) | Hsd17b13 inhibitors and uses thereof | |
| AR042653A1 (es) | Derivados sustiuidos de 1- piperidin -3- il- 4- piperidin 4- -il- piperazina y su uso como antagonistas de taquiquininas | |
| CA2509090A1 (en) | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists | |
| WO2005087775A1 (ja) | 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物 | |
| AR040974A1 (es) | Derivados heterociclicos de isoxazolina fusionados y su uso como antidepresivos | |
| AR041020A1 (es) | Derivados de isoxazolina c6- y c9- substituidos; su uso para la manufactura de un medicamento y composicion farmaceutica | |
| CA3186117A1 (en) | Cyclic cyanoenone derivatives as modulators of keap1 | |
| JO2526B1 (en) | Substituted 1-4 Dipyridine-4-YL-Piprazine derivatives and their use as NSAIDs | |
| MXPA05003778A (es) | Derivados sustituidos de la 1,4-di-piperidin-4-il-piperazina y su uso como antagonistas de neurocininas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |